Published in J Diabetes Res on February 09, 2015
Adenosine Monophosphate-activated Protein Kinase (AMPK) Activators For the Prevention, Treatment and Potential Reversal of Pathological Pain. Curr Drug Targets (2016) 0.76
Pioglitazone Inhibits the Development of Hyperalgesia and Sensitization of Spinal Nociresponsive Neurons in Type 2 Diabetes. J Pain (2015) 0.76
Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care (2004) 75.82
Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol (2010) 27.58
Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods (1994) 23.05
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet (2006) 15.76
Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. N Engl J Med (1976) 7.02
The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res (2001) 6.59
Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest (2002) 5.31
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med (1995) 4.29
The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology (1993) 4.18
Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res (2005) 3.96
Pioglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev (2006) 2.59
A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism (2000) 2.49
Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice. Diabetologia (2010) 2.40
Chemokines, neuronal-glial interactions, and central processing of neuropathic pain. Pharmacol Ther (2010) 2.27
Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care (2011) 1.88
Astrocyte intermediate filaments in CNS pathologies and regeneration. J Pathol (2004) 1.87
High-fat diet induced neuropathy of pre-diabetes and obesity: effects of "healthy" diet and aldose reductase inhibition. Diabetes (2007) 1.85
Diabetic painful and insensate neuropathy: pathogenesis and potential treatments. Neurotherapeutics (2009) 1.75
Prevalence, predisposition and prevention of type II diabetes. Nutr Metab (Lond) (2005) 1.73
Local translation in primary afferent fibers regulates nociception. PLoS One (2008) 1.70
Nongenetic mouse models of non-insulin-dependent diabetes mellitus. Metabolism (1998) 1.54
Early painful diabetic neuropathy is associated with differential changes in tetrodotoxin-sensitive and -resistant sodium channels in dorsal root ganglion neurons in the rat. J Biol Chem (2004) 1.43
Descending facilitation from the rostral ventromedial medulla maintains nerve injury-induced central sensitization. Neuroscience (2006) 1.39
ERK1/2 mitogen-activated protein kinase phosphorylates sodium channel Na(v)1.7 and alters its gating properties. J Neurosci (2010) 1.38
Diabetes-induced mechanical hyperalgesia involves spinal mitogen-activated protein kinase activation in neurons and microglia via N-methyl-D-aspartate-dependent mechanisms. Mol Pharmacol (2006) 1.37
Targeting adenosine monophosphate-activated protein kinase (AMPK) in preclinical models reveals a potential mechanism for the treatment of neuropathic pain. Mol Pain (2011) 1.32
Tactile allodynia and formalin hyperalgesia in streptozotocin-diabetic rats: effects of insulin, aldose reductase inhibition and lidocaine. Pain (1996) 1.27
Tonic modulation of spinal hyperexcitability by the endocannabinoid receptor system in a rat model of osteoarthritis pain. Arthritis Rheum (2010) 1.27
Brief, low frequency stimulation of rat peripheral C-fibres evokes prolonged microglial-induced central sensitization in adults but not in neonates. Pain (2009) 1.24
Electrophysiological characterization of spinal neuronal response properties in anaesthetized rats after ligation of spinal nerves L5-L6. J Physiol (1998) 1.15
The anti-diabetic drug metformin protects against chemotherapy-induced peripheral neuropathy in a mouse model. PLoS One (2014) 1.13
Renal and cardiac effects of DPP4 inhibitors--from preclinical development to clinical research. Kidney Blood Press Res (2012) 1.12
Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice. Diabetes (2011) 1.10
Modeling type 2 diabetes in rats using high fat diet and streptozotocin. J Diabetes Investig (2014) 1.09
Activation of dorsal horn microglia contributes to diabetes-induced tactile allodynia via extracellular signal-regulated protein kinase signaling. Glia (2008) 1.09
Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats. Arch Med Res (2009) 1.08
Pain behavior and response properties of spinal dorsal horn neurons following experimental diabetic neuropathy in the rat: modulation by nitecapone, a COMT inhibitor with antioxidant properties. Exp Neurol (2001) 1.07
Pioglitazone, a PPARgamma agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats. Cardiovasc Res (2005) 1.06
Phenotypic changes in diabetic neuropathy induced by a high-fat diet in diabetic C57BL/6 mice. Exp Diabetes Res (2011) 1.06
Spinal astrocytes as therapeutic targets for pathological pain. J Pharmacol Sci (2010) 1.04
Rapid pain modulation with nuclear receptor ligands. Brain Res Rev (2008) 1.03
Gabapentin reverses microglial activation in the spinal cord of streptozotocin-induced diabetic rats. Eur J Pain (2008) 1.02
Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity. PLoS One (2012) 1.01
PPARγ activation blocks development and reduces established neuropathic pain in rats. Neuropharmacology (2013) 1.00
Behavioral and electrophysiological studies in rats with cisplatin-induced chemoneuropathy. Brain Res (2008) 0.98
Mechanical hyperalgesia correlates with insulin deficiency in normoglycemic streptozotocin-treated rats. Neurobiol Dis (2006) 0.97
Tetrodotoxin-resistant sodium channels of dorsal root ganglion neurons are readily activated in diabetic rats. Neuroscience (1999) 0.95
Maladaptive dendritic spine remodeling contributes to diabetic neuropathic pain. J Neurosci (2012) 0.92
Spinal astrocytic activation contributes to mechanical allodynia in a mouse model of type 2 diabetes. Brain Res (2010) 0.91
Effects of diabetes mellitus on astrocyte GFAP and glutamate transporters in the CNS. Glia (2004) 0.90
Beneficial effects of PKF275-055, a novel, selective, orally bioavailable, long-acting dipeptidyl peptidase IV inhibitor in streptozotocin-induced diabetic peripheral neuropathy. J Pharmacol Exp Ther (2011) 0.89
Effects of high-fat diet and the anti-diabetic drug metformin on circulating GLP-1 and the relative number of intestinal L-cells. Diabetol Metab Syndr (2014) 0.88
Comparison of the antinociceptive effect of celecoxib, diclofenac and resveratrol in the formalin test. Life Sci (2002) 0.88
Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. Metabolism (2014) 0.85
DPP-4 Inhibitor Teneligliptin Improves Insulin Resistance and Serum Lipid Profile in Japanese Patients with Type 2 Diabetes. Drug Res (Stuttg) (2014) 0.84
Basolateral amygdala lesion inhibits the development of pain chronicity in neuropathic pain rats. PLoS One (2013) 0.84
Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes. Diabetes Obes Metab (2012) 0.84
Effects of acute exercise and chronic exercise on the liver leptin-AMPK-ACC signaling pathway in rats with type 2 diabetes. J Diabetes Res (2013) 0.83
Repeated administration of pioglitazone attenuates development of hyperalgesia in a rat model of neuropathic pain. Exp Clin Psychopharmacol (2010) 0.83
Establishment of a rat model of type II diabetic neuropathic pain. Pain Med (2014) 0.82
Insulin treatment prevents diabetes-induced alterations in astrocyte glutamate uptake and GFAP content in rats at 4 and 8 weeks of diabetes duration. Brain Res (2009) 0.81
Persistent mechanical allodynia positively correlates with an increase in activated microglia and increased P-p38 mitogen-activated protein kinase activation in streptozotocin-induced diabetic rats. Eur J Pain (2013) 0.81
Exposure to the saturated free fatty acid palmitate alters BV-2 microglia inflammatory response. J Mol Neurosci (2013) 0.80
Alteration of glial fibrillary acidic proteins immunoreactivity in astrocytes of the spinal cord diabetic rats. Anat Rec (Hoboken) (2008) 0.80
Expression of calcium/calmodulin-dependent protein kinase II and pain-related behavior in rat models of type 1 and type 2 diabetes. Anesth Analg (2013) 0.79
Synergistic action of thyroid hormone, insulin and hydrocortisone on astrocyte differentiation. Brain Res (1987) 0.78
Pioglitazone attenuates tactile allodynia and microglial activation in mice with peripheral nerve injury. Drug Discov Ther (2008) 0.78
Yi-Qi-Zeng-Min-Tang, a Chinese medicine, ameliorates insulin resistance in type 2 diabetic rats. World J Gastroenterol (2011) 0.78
A novel spinal action of mexiletine in spinal somatosensory transmission of nerve injured rats. Pain (1998) 0.78
Effects of the DPP-4 inhibitor, linagliptin, in diet-induced obese rats: a comparison in naive and exenatide-treated animals. Clin Lab (2012) 0.78
Effect of KIOM-79 on Diabetes-Induced Myocardial Fibrosis in Zucker Diabetic Fatty Rats. Evid Based Complement Alternat Med (2013) 0.78
Reduced epidermal thickness, nerve degeneration and increased pain-related behavior in rats with diabetes type 1 and 2. J Chem Neuroanat (2013) 0.77